PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy
Simeng Wang(First Affiliated Hospital of Xi'an Jiaotong University), Chunfu Wu(Shenyang Pharmaceutical University)
Cited by 10
Related Papers
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
|British Journal of Cancer|2017|77